Two radically new gene based immunotherapies were approved by the FDA this year – Kymriah followed by Yescarta – in August and October, respectively. Approved in August 2017, before Novartis named the drug Kymriah (Tisagenlecleucel) – it…
TrialX is excited to participate and present in AMIA 2017, the 41st anniversary of the annual symposia conducted by the American Medical Informatics Association (AMIA). Every year, leading informaticians such as – translational scientists, clinicians,…
iConnect 2.0 is a specifically designed online platform that facilitates patient-recruitment for academic medical centers, sponsors, and patient advocacy groups. iConnect 2.0 helps overcome challenges of patient recruitment in clinical trials by: Creating a…
Our CEO, Dr. Sharib Khan did the unimagined and gave true meaning to DISRUPTION when he did a headstand while presenting Appbakery – turning clinical research upside down literally – at the Mobile in Clinical Trials…
As proved now by several preliminary studies performed by prestigious organizations, use of mobile technology in clinical trials can improve efficiency of the clinical research industry. It offers several merits such as: Continuous acquisition of data,…
Today we live in an era where we cannot underscore enough, the importance of informed consent in research and treatment – for the safety of patients as well as the physicians treating them. Digital technology…
We are excited to participate and present at the 7th annual DPharm: Disruptive Innovations to Advance Clinical Trials (#Dpharm2017) conference in Boston in the first week of September 2017. The first day of this conference, Sepetember…